CBR1 and amyotrophic lateral sclerosis: Data from experimental ALS using nonselective CBR agonists (such as WIN 55,212-2) and selective CB2R agonists suggest the prominent contribution of CB2R and CB2R-mediated suppression of reactive microgliosis in beneficial effects of cannabinoids in ALS.